Qualified researchers studying endocrine signalling, metabolic function, or growth-hormone-releasing pathways are increasingly turning to CJC-1295 peptide as a subject of controlled laboratory investigation. At PeptideValidation.com, we supply it as a 5 mg lyophilized powder intended strictly for in-vitro and preclinical research, not for human or veterinary use. This overview covers the compound's structure, its DAC and non-DAC forms, research dosage notes, quality-verification standards, and what the current science actually says. Nothing here is medical advice.

What Is CJC-1295 Peptide?

CJC-1295 is a synthetic analogue of growth-hormone-releasing hormone (GHRH) composed of 30 amino acids. It mimics the first 29 residues of endogenous GHRH while adding a modified lysine at position 29 that extends its half-life significantly beyond the 7-minute clearance typical of native GHRH fragments.

CJC-1295 was first described in peer-reviewed literature around 2006 and is classified as a GHRH analogue, not a steroid. Researchers sometimes ask "is CJC-1295 a steroid?" The short answer is no. It is a peptide, meaning it is a chain of amino acids, not a cholesterol-derived molecule. That distinction matters for how you store it, how you handle it in a lab setting, and how it interacts with the growth-hormone axis.

The compound exists in two primary research forms. One carries a Drug Affinity Complex (DAC) modification, commonly written as CJC-1295 DAC or "CJC-1295 with DAC." The other omits the DAC and is sometimes labelled Modified GRF 1-29. The DAC unit is a maleimidopropionic acid linker that allows the peptide to bind covalently to circulating albumin, dramatically extending its plasma half-life from roughly 30 minutes to an estimated 6 to 8 days in animal models.

In laboratory contexts, the CJC-1295 dac peptide is used when researchers want to study sustained stimulation of GH-releasing pathways over longer observation windows. The non-DAC form is preferred when investigators need tighter control over the duration of exposure. Knowing which variant you have in your study design is critical before any experiment begins.

How CJC-1295 Works in Growth-Hormone-Releasing Pathways

CJC-1295 binds to GHRH receptors on pituitary somatotroph cells, triggering a cAMP-mediated signalling cascade that stimulates synthesis and pulsatile release of growth hormone. Because the DAC form binds albumin, it produces a prolonged receptor occupancy pattern not seen with native GHRH.

At the molecular level, CJC-1295 peptide mimics endogenous GHRH by occupying the same receptor (GHRHR) on anterior pituitary cells. Binding activates adenylyl cyclase, raises intracellular cyclic AMP, and promotes GH secretion in a pattern that mirrors normal pulsatile physiology, at least in short-duration animal studies.

Researchers investigating this signalling cascade commonly combine CJC-1295 with a ghrelin mimetic such as ipamorelin to study synergistic effects on GH pulse amplitude. This combination approach appears frequently in preclinical endocrinology literature precisely because each agent targets a different receptor, creating what some investigators describe as an additive stimulation effect.

IGF-1 is often the downstream biomarker measured in these studies. A 2006 paper by Jetty Dimitriadis et al. in Growth Hormone and IGF Research reported that CJC-1295 produced sustained, dose-dependent increases in serum GH and IGF-1 in healthy adult subjects during a Phase I trial. That finding gave the research community a useful baseline for designing later animal and cell-culture studies.

For laboratories at PeptideValidation.com focused on metabolic or endocrine research, understanding this receptor pharmacology is what determines which assay endpoints make sense, how long you need to monitor cells or animal models, and what controls you should include.

CJC-1295 With DAC Dosage: What the Research Literature Reports

Published preclinical and early clinical research on CJC-1295 with DAC dosage typically describes ranges of 30 mcg/kg to 60 mcg/kg administered once or twice weekly in animal models, reflecting the compound's extended half-life. These figures are reference points for study design only and do not constitute recommendations for human use.

The CJC-1295 with DAC dosage question is one of the most common queries from researchers designing GH-axis studies. The key factor is the DAC modification. Because the compound has a half-life of roughly 6 to 8 days in rodent models, most published protocols use once-weekly or twice-weekly administration rather than the daily schedules used for non-DAC GHRH analogues.

A 2006 human Phase I/II trial explored doses between 30 mcg/kg and 60 mcg/kg and observed dose-dependent GH and IGF-1 elevations that persisted for up to 14 days post-injection. Researchers working in cell-culture or ex-vivo settings often scale these figures down substantially, sometimes to nanomolar concentrations, depending on the assay format.

For non-DAC formulations (Modified GRF 1-29), published schedules tend to mirror the shorter half-life, with multiple administrations per day in animal protocols. CJC-1295 peptide dosage in these designs is typically expressed per gram of body weight and calibrated to the specific rodent strain and study endpoint.

Always align your dosage design with your institutional review and ethics documentation. The figures above come from published literature and are intended as study design reference points, not protocols to be applied outside a controlled research environment. PeptideValidation.com provides batch-specific Certificates of Analysis (COAs) with each supply so researchers can confirm exact concentration and purity before planning any dosing regimen.

CJC-1295 Peptide Benefits Observed in Preclinical Research

Preclinical research on CJC-1295 peptide benefits has focused on four areas: sustained GH pulse amplitude, downstream IGF-1 modulation, body composition changes in rodent models, and extended receptor engagement compared with native GHRH. These are laboratory observations, not clinical claims.

The phrase "CJC-1295 peptide benefits" gets used loosely online. In a strict research context, what the literature actually documents is a set of observed biological effects in animal and early human trial settings.

Sustained GH secretion. The DAC form maintained elevated GH levels for up to two weeks in human subjects in the 2006 Phase I trial, a profile that distinguishes it from shorter-acting GHRH fragments. That sustained signal is precisely what makes it a useful tool for studying tonic versus pulsatile GH axis dynamics.

IGF-1 modulation. Multiple animal studies have recorded elevated circulating IGF-1 following CJC-1295 administration. IGF-1 is a key downstream effector of GH signalling and a standard biomarker in metabolic and growth research.

Body composition changes in rodents. Several rodent studies noted shifts in lean mass and fat mass distribution following chronic CJC-1295 treatment. These findings are preliminary and limited to controlled animal models.

Receptor selectivity. Because CJC-1295 targets GHRHR rather than androgen or glucocorticoid receptors, researchers can study GH-axis effects without the confounding variables that come with steroid-based interventions.

None of these observations constitute evidence of safety or efficacy in humans. They are research signals that help laboratories design more precise follow-up studies.

CJC-1295 Side Effects Reported in Early-Phase Research

CJC-1295 side effects noted in early-phase human trials included transient facial flushing, injection-site reactions, and headache at higher doses. No serious adverse events were attributed to the compound in published Phase I data, though the research population was small and observation periods were short.

Researchers reviewing CJC-1295 side effect data should start with the 2006 Teichman et al. publication in the Journal of Clinical Endocrinology and Metabolism. That Phase II trial in 65 healthy adults documented mild, transient effects at doses up to 60 mcg/kg, including flushing, water retention sensations, and localised injection-site discomfort. No serious adverse events were reported during the observation window.

In rodent toxicology studies, the picture is similarly limited. Most published data comes from short-duration studies (under 90 days), which means long-term safety profiles in animal models are not well characterised in peer-reviewed literature as of mid-2026.

For laboratory researchers, these observations have practical implications. When designing in-vitro or cell-based studies, off-target receptor binding is a variable to control for, particularly if your assay system expresses multiple GPCR family receptors. In ex-vivo tissue preparations, pituitary cell viability at higher peptide concentrations is a checkpoint worth building into your protocol.

Peptide purity directly affects how reliably you can attribute any observed cellular response to CJC-1295 itself rather than to contaminants. This is why HPLC purity data on the COA matters so much. A batch at 95% purity and a batch at 98% purity can behave differently in a sensitive bioassay.

How to Verify Quality Before Starting Any CJC-1295 Research Study

Quality verification for CJC-1295 research compounds should include five checks: (1) HPLC purity above 98%, (2) mass spectrometry identity confirmation, (3) batch-specific COA with lot number, (4) independent third-party testing documentation, and (5) lyophilized powder format with confirmed storage conditions.

Sourcing matters as much as study design. A compound labelled "CJC-1295" can vary enormously in actual purity, sequence fidelity, and moisture content depending on the supplier's manufacturing controls. Buying CJC-1295 peptide without reviewing the underlying analytical documentation is a fast route to irreproducible results.

Here is what a credible COA for research-grade CJC-1295 should show:

• Peptide identity: Confirmed by ESI-MS or MALDI-TOF with a molecular weight match to the theoretical value of approximately 3367.97 Da (for the non-DAC form).
• HPLC purity: At least 98% by area under the curve. Anything below 95% introduces significant contaminant variables.
• Peptide content: Not the same as purity. This accounts for moisture and counterion mass, often expressed as a percentage of net peptide.
• Batch and lot number: Traceable to a specific manufacturing run.
• Storage conditions: Lyophilized CJC-1295 is typically stable at -20 degrees Celsius. Reconstituted solutions have shorter stability windows.

PeptideValidation.com evaluates vendors against these criteria and publishes those assessments so researchers can make informed sourcing decisions. The 5 mg lyophilized powder format we supply is specifically chosen because it provides a stable, accurately weighed starting material for laboratory reconstitution. You control the concentration from the beginning.

For a broader discussion of verification standards and how they apply across CJC-1295 research, see our complete research guide linked below.

CJC-1295 Peptide Price and Research Budget Considerations

CJC-1295 peptide price for research-grade material typically ranges from $40 to $120 per 5 mg vial as of mid-2026, depending on purity specifications, vendor certification status, and whether the DAC modification is included. Significantly lower prices are a flag for reduced purity or absent third-party testing.

Budget planning for peptide research involves more than the purchase price of the compound itself. Researchers should factor in reconstitution supplies (bacteriostatic water, sterile vials, low-bind syringes), cold-chain shipping costs, and the time cost of re-running experiments if a low-quality batch produces inconsistent results.

As of August 2026, CJC-1295 peptide buy decisions in academic and commercial labs are increasingly driven by COA quality rather than price alone. Grant reviewers and institutional biosafety committees increasingly ask for supplier documentation, which means buying from a vendor that cannot provide third-party analytical testing creates downstream administrative friction.

The DAC form typically costs more than the non-DAC version because of the additional synthesis step involved in adding the maleimidopropionic acid linker. That price difference is legitimate. Be cautious of listings that offer DAC-modified peptide at the same price point as the simpler non-DAC form.

Storage also affects total cost of ownership. Lyophilized powder stored at -20 degrees Celsius retains stability for 24 months or longer in most published stability studies. Reconstituted solutions, depending on the buffer system, may degrade within 30 days. Buying in powder form and reconstituting in small aliquots is generally more economical for laboratories running periodic rather than continuous assays.

Frequently asked questions

Related in this series

• Understanding CJC-1295 Peptide: A Researcher's Guide